Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

9 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-09-30

Study Completion Date

2017-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chronic blood transfusions are essential supportive care for sickle cell patients at high risk for morbidity and mortality due to stroke. These patients, however, are at risk for iron overload. In the investigator's comprehensive sickle cell center, the investigators support chronic transfusion with rapid manual partial exchange transfusions (RMPET) using a single access central line port. The investigators do not have a comprehensive adult sickle cell program but upon transition of patients the patients would be provided simple transfusion (ST) in an adult ambulatory infusion setting due to nursing acuity needed for RMPET. The investigators plan to study the institution's participants currently on chronic transfusion support and compare different transfusion modalities to better understand the effects from switching from RMPET to ST. To date, there are no such comparisons within and between sickle cell patients in the literature.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Stroke Prevention in Sickle Cell Anemia (STOP 2)

NCT00006182

Blood Disease Cerebrovascular Accident Anemia, Sickle Cell

COMPLETED PHASE3

Stroke Prevention in Sickle Cell Anemia (STOP 1)

NCT00000592

Anemia, Sickle Cell Cerebral Embolism and Thrombosis Cerebrovascular Disorders +2 more

COMPLETED PHASE3

Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial

NCT00072761

Sickle Cell Anemia Stroke

COMPLETED PHASE3

Allogeneic Genoidentical Stem Cell Transplantation in Children With Sickle-cell Anemia and Cerebral Vasculopathy

NCT01340404

Sickle Cell Anemia Cerebrovascular Accident

COMPLETED NA

Stroke Prevention in Young Adults With Sickle Cell Anemia

NCT04808778

Sickle Cell Disease Sickle Cell Anemia Stroke, Ischemic +3 more

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

II. Objective. Compare differences in RMPET versus ST.

III. Specific Aims:

1. To compare key predictive hematologic factors (hematocrit, hemoglobin, hemoglobin S quantification, blood volume and alloantibodies) for relative risk of stroke utilizing two methods of blood transfusion therapy.
2. To determine the nursing time to administer straight versus manual exchange transfusion therapy.
3. To survey patient satisfaction for both procedures.

IV: Background/Significance:

Stroke occurs in 10% of Sickle Cell Disease (SCD) patients before the age of 20 Years. Current standard of care for secondary overt stroke prevention in patients with SCD is chronic red blood cell (RBC) transfusions. Stroke recurs in \~ 60% of patients without chronic RBC therapy and in \~ 20% of patients with chronic transfusion while maintaining a hemoglobin S percentage of less than 30%. Indefinite transfusion therapy is practiced as discontinuation after short-term or long-term prophylactic transfusions leads to recurrent overt strokes and more ensuing CNS damage, even with transition to hydroxyurea. Chronic transfusions also prevent initial stroke in high-risk patients identified by transcranial Doppler (TCD) ultrasound. The Stroke Prevention Study in Sickle Cell Disease (STOP) demonstrated a 92% stroke risk reduction among 63 of 130 children with abnormal TCD results. Rates of stroke declined significantly since implementing routine TCD screening and primary prophylactic transfusion therapy. The subsequent STOP 2 trial supports the use of chronic transfusion indefinitely because discontinuation resulted in an increased rate of abnormal TCD conversion and development of overt stroke. Discontinuing transfusions on the STOP 2 trial was also associated with a higher occurrence of silent cerebral infarcts, documented in 3 of 37 patients (8.1%) in the continued-transfusion group compared with 11 of 40 (27.5%) in the transfusion-halted group. More recent studies demonstrate that SCD patients are also at risk for silent cerebral infarcts. An association between worsening vasculopathy shown by magnetic resonance angiography and progressive overt and silent infarcts on magnetic resonance imaging has been found. More aggressive magnetic resonance imaging screening may be indicated and this could result in more patients with SCD treated with chronic transfusion.

Common chronic transfusion modalities include ST or RMPET. The goal of therapy is to reduce the hemoglobin S level either by diluting the blood (ST) or by removing and replacing the blood with non-sickle hemoglobin (RMPET). To prevent further brain injury, the goal of transfusion therapy is to lower the hemoglobin S quantification to less than 30% on a routine basis, usually monthly transfusion procedure. There are many large centers that utilize erythrocytapheresis which is considered the preferable method if available.

The investigator's study will focus on the types of RBC exchange therapy currently utilized in the investigator's Infusion Clinic at T.C. Thompson Children's Hospital. The investigators will determine which transfusion method is best for each participant for achieving the hematologic parameters of lower hemoglobin S quantification.The investigators will also measure the amount of nursing time for each procedure and which method is preferred by participants. The investigators will share the institutional observations with other institutions who may intend to switch between RMPET and ST.

V. Methods:

Study Design: Prospective observational cohort study

The investigators will utilize the institution's current population of 8 eligible chronically exchanged transfused participants at the T.C. Thompson Children's Infusion Clinic. The eligible participants will be invited to participate in a cross over design study so that each participant serves as its own control. Eight participants will be randomly assigned (blinded envelope) whereby four participants will start with rapid manual partial exchange transfusion: 3 months will be spent in a wash out period, then 3 months of data collection for RMPET. This group will then be switched to simple transfusion with a wash out period of three months, then data collection for three months. The second group of four participants will start with simple transfusion and have an identical study design over 12 months (3 months of collected data during simple transfusion, a 3 month wash out period, switch to rapid manual partial exchange transfusion for three months, then 3 months of data collection for RMPET).

The investigators will optimize all therapy to achieve the post transfusion goal of \<30% hemoglobin S and post transfusion Hb \<12g/DL.with each transfusion performed for best practice in avoiding sickle cell complications.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anemia, Sickle Cell Sickling Disorder Due to Hemoglobin S

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CROSSOVER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RMPET

For rapid manual partial exchange transfusion, participants with a weight \>50kg, 500 ml of whole blood is removed from the participant via a single lumen central venous line, followed by infusion of 500 ml of saline. A 30 second wait time is utilized for equilibration to occur. A second 500 ml aliquot is removed, and then two units of packed red blood cells (PRBC) are infused. (This is customized for a patient with large red blood cell mass). For participants \<50 kg, the individual exchange aliquots are adjusted to 10 ml/kg or normal saline and PRBC.

Rapid manual partial exchange transfusion

Intervention Type OTHER

The first four participants will receive peripheral red blood cells via rapid manual partial exchange transfusions every month for 6 months. There is a pre-study washout for 3 months then there is a 3 month test period (data collection) before the participant is transferred to ST treatment.

Simple Transfusion

For simple transfusion, the volume of packed red blood cells (PRBC) to be transfused in the participant is 10-15 cc/kg. No normal saline exchange is required. All blood is transfused through a single lumen central venous line.

Simple Transfusion

Intervention Type OTHER

The second group of four participants will receive peripheral red blood cells via simple transfusion every month for 6 months. There is a pre-study washout period for 3 months then there is a 3 month test period (data collection) before the participant is transferred to RMPET treatment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rapid manual partial exchange transfusion

The first four participants will receive peripheral red blood cells via rapid manual partial exchange transfusions every month for 6 months. There is a pre-study washout for 3 months then there is a 3 month test period (data collection) before the participant is transferred to ST treatment.

Intervention Type OTHER

Simple Transfusion

The second group of four participants will receive peripheral red blood cells via simple transfusion every month for 6 months. There is a pre-study washout period for 3 months then there is a 3 month test period (data collection) before the participant is transferred to RMPET treatment.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Participants between 3 and 25 years of age
2. Diagnosis of Hemoglobin SS or SBeta thalassemia
3. On chronic exchange for stroke prevention
4. Performance status: Lansky play score of 100%, and if over 16 years of age, Karnofsky=100%

Exclusion Criteria

1. Participant has experienced more than one stroke and has a modified Rankin Scale of \>3.
2. Diagnosis of Hemoglobin SC disease
3. Participants on chronic transfusion for priapism.

Minimum Eligible Age

3 Years

Maximum Eligible Age

25 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No